文献速递浆细胞疾病造血干细胞移植与细胞治疗

携带mRNA编码肿瘤抗原的朗格汉斯树突状细胞疫苗在自体移植后诱导抗骨髓瘤免疫

Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.
PubMed 文献 · Blood Adv · 2022-01-01

这项1期疫苗试验评估了自体朗格汉斯型树突状细胞(LCs)电转CT7、MAGE-A3和WT1 mRNA疫苗在骨髓瘤自体干细胞移植(ASCT)后的安全性、毒性和免疫原性。10例患者接种疫苗,10例对照未接种但接受相同ASCT和支持治疗,所有患者移植后3个月开始来那度胺维持治疗。疫苗接种安全,仅出现1级毒性,并诱导了抗原特异性CD4和CD8 T细胞反应。

要点

  • ASCT后接种携带CT7、MAGE-A3和WT1 mRNA的自体LC疫苗安全,未出现超过1级的毒性。
  • 疫苗诱导抗原特异性CD4和CD8 T细胞增加促炎细胞因子分泌并上调CD107a。
  • T细胞受体库分析显示疫苗组克隆扩增呈增加趋势,以CD4 compartment更明显。

核心结论

  • 在ASCT植入后开始接种携带三种抗原的mRNA电转自体LC疫苗,联合标准来那度胺维持治疗,对多发性骨髓瘤是安全的,并诱导抗原特异性免疫反应。

研究设计与样本

  • 1期疫苗试验,10例患者接种自体朗格汉斯型树突状细胞(LCs)疫苗,电转CT7、MAGE-A3和WT1 mRNA。
  • 疫苗接种组在ASCT后12、30和90天分别接受初次免疫和2次加强免疫,每次疫苗含9×10^6个mRNA电转LCs。
  • 另10例患者未接种LC疫苗,但接受相同ASCT和支持治疗;所有患者在ASCT后3个月开始来那度胺维持治疗。
  • 试验注册号NCT01995708。

主要发现

  • 接种疫苗的患者在加强免疫后出现轻度局部迟发型超敏反应,但无毒性超过1级。
  • 在疫苗接种后1个月和3个月,抗原特异性CD4和CD8 T细胞分泌干扰素-γ、白细胞介素-2和肿瘤坏死因子-α较疫苗前水平增加,并上调细胞毒性标志物CD107a。
  • CD4和CD8 T细胞受体库分析显示疫苗组克隆扩增呈增加趋势,在CD4 compartment更为明显。
  • 虽未以评估临床疗效为效能,治疗反应倾向于疫苗组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Posttransplant vaccination targeting residual disease is an immunotherapeutic strategy to improve antigen-specific immune responses and prolong disease-free survival after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We conducted a phase 1 vaccine trial to determine the safety, toxicity, and immunogenicity of autologous Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and Wilms tumor 1 (WT1) messenger RNA (mRNA), after ASCT for MM. Ten patients received a priming immunization plus 2 boosters at 12, 30, and 90 days, respectively, after ASCT. Vaccines contained 9 × 106 mRNA-electroporated LCs. Ten additional patients did not receive LC vaccines but otherwise underwent identical ASCT and supportive care. At 3 months after ASCT, all patients started lenalidomide maintenance therapy. Vaccinated patients developed mild local delayed-type hypersensitivity reactions after booster vaccines, but no toxicities exceeded grade 1. At 1 and 3 months after vaccines, antigen-specific CD4 and CD8 T cells increased secretion of proinflammatory cytokines (interferon-γ, interleukin-2, and tumor necrosis factor-α) above prevaccine levels, and also upregulated the cytotoxicity marker CD107a. CD4 and CD8 T-cell repertoire analysis showed a trend for increased clonal expansion in the vaccine cohort, which was more pronounced in the CD4 compartment. Although not powered to assess clinical efficacy, treatment responses favored the vaccine arm. Triple antigen-bearing mRNA-electroporated autologous LC vaccination initiated at engraftment after ASCT, in conjunction with standard lenalidomide maintenance therapy for MM, is safe and induces antigen-specific immune reactivity. This trial was registered at www.clinicaltrials.gov as #NCT01995708.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chung DJ, Sharma S, Rangesa M, et al. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant. Blood Adv. 2022. PMID: 35100339. doi:10.1182/bloodadvances.2021005941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。